Recombinant DNA vaccine of the early secreted antigen ESAT-6 by Mycobacterium tuberculosis and Flt3 ligand enhanced the cell-mediated immunity in mice

Vaccine

Volumn 26, Issue 35, 2008, Pages 4519-4525

  Xu, Juan ^a   Xu, Wenhuan ^a   Chen, Xia ^a   Zhao, Dan ^a   Wang, Yingwei ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

6 kDa early secretary antigenic target; Cell mediated immune; Flt3 ligand; Mycobacterium tuberculosis; Recombinant DNA vaccine

Indexed keywords

ALPHA TUBULIN; BCG VACCINE; DNA VACCINE; EARLY SECRETORY ANTIGENIC TARGET 6; FLT3 LIGAND; GAMMA INTERFERON; GROWTH FACTOR; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; PLASMID DNA; RECOMBINANT DNA VACCINE; RECOMBINANT VACCINE; T LYMPHOCYTE ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIBODY BLOOD LEVEL; ANTIBODY SPECIFICITY; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; FEMALE; GENETIC TRANSFECTION; IMMUNIZATION; INTERFERON PRODUCTION; INTERNAL RIBOSOME ENTRY SITE; LUNG TUBERCULOSIS; LYMPHOCYTE PROLIFERATION; MESANGIUM; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RESTRICTION MAPPING; SEQUENCE ANALYSIS; SPLEEN CELL; T LYMPHOCYTE; TH1 CELL; TH2 CELL; WESTERN BLOTTING;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BLOTTING, WESTERN; FEMALE; IMMUNITY, CELLULAR; IMMUNIZATION, SECONDARY; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-2; INTERLEUKIN-4; MEMBRANE PROTEINS; MESANGIAL CELLS; MICE; MICE, INBRED C57BL; MYCOBACTERIUM TUBERCULOSIS; PLASMIDS; RATS; SPLEEN; TH1 CELLS; TRANSFECTION; TUBERCULOSIS VACCINES; VACCINES, DNA;

EID: 48449090795     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.06.044     Document Type: Article

References (33)

1. Global tuberculosis control: surveillance, planning, financing. WHO report 2007, (WHO/HTM/TB/2007.376). Geneva: World Health Organization; 2007.
2. Colditz G.A., Brewer T.F., Berkley C.S., Wilson M.E., Burdick E., Fineberg H.V., et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta analysis of the published literature. JAMA 271 9 (1994) 698-702
3. Ravn P., Demissie A., Eguale T., Wondwosson H., Lein D., Amoudy H.A., et al. Human T cell responses to the ESAT-6 antigen from Mycobacterium tuberculosis. J Infect Dis 179 3 (1999) 637-645
4. Brandt L., Elhay M., Rosenkrands I., Lindblad E.B., and Andersen P. ESAT-6 subunit vaccination against Mycobacterium tuberculosis. Infect Immun 68 2 (2000) 791-795
5. Behr M.A., Wilson M.A., Gill W.P., Salamon H., Schoolnik G.K., Rane S., et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 284 5419 (1999) 1520-1523
6. Gordon S.V., Brosch R., Billault A., Garnier T., Eiqlmeier K., and Cole S.T. Identification of variable regions in the genomes of tubercle bacilli using bacterial artificial chromosome arrays. Mol Microbiol 32 3 (1999) 643-655
7. Pathak S.K., Basu S., Basu K.K., Banerjee A., Pathak S., Bhattacharyya A., et al. Direct extracellular interaction between the early secreted antigen ESAT-6 of Mycobacterium tuberculosis and TLR2 inhibits TLR signaling in macrophages. Nat Immunol 8 6 (2007) 610-618
8. Stanley S.A., Raghavan S., Hwang W.W., and Cox J.S. Acute infection and macrophage subversion by Mycobacterium tuberculosis require a specialized secretion system. Proc Natl Acad Sci USA 100 22 (2003) 13001-13006
9. Hughes A.J., Hutchinson P., Gooding T., Freezer N.J., Holdsworth S.R., and Johnson P.D. Diagnosis of Mycobacterium tuberculosis infection using ESAT-6 and intracellular cytokine cytometry. Clin Exp Immunol 142 1 (2005) 132-139
10. Pulendran B., Banchereau J., Maraskovsky E., and Maliszewski C. Modulating the immune response with dendritic cells and their growth factors. Trends. Immunol 22 1 (2001) 41-47
11. Antonysamy M.A., and Thomson A.W. Flt3 ligand (FL) and its influence on immune reactivity. Cytokine 12 2 (2000) 87-100
12. Harada S., Kimura T., Fujiki H., Nakagawa H., Ueda Y., Itoh T., et al. Flt3 ligand promotes myeloid dendritic cell differentiation of human hematopoietic progenitor cells: possible application for cancer immunotherapy. Int J Oncol 30 6 (2007) 1461-1468
13. Chen W., Chan A.S., Dawson A.J., Liang X., Blazar B.R., and Miller J.S. FLT3 ligand administration after hematopoietic cell transplantation increases circulating dendritic cell precursors that can be activated by CpG oligodeoxynucleotides to enhance T-cell and natural killer cell function. Biol. Blood Marrow Tr 11 1 (2005) 23-34
14. Sang H., Pisarev V.M., Munger C., Robinson S., Chavez J., Hatcher L., et al. Regional, but not systemic recruitment/expansion of dendritic cells by a pluronic-formulated Flt3-ligand plasmid with vaccine adjuvant activity. Vaccine 21 21-22 (2003) 3019-3029
15. Toliver-Kinsky T.E., Cui W., Murphey E.D., Lin C., and Sherwood E.R. Enhancement of dendritic cell production by fms-like tyrosine kinase-3 ligand increases the resistance of mice to a burn wound infection. J Immunol 174 1 (2005) 404-410
16. Hannum C., Culpepper J., Campbell D., McClanahan T., Zurawski S., Bazan J.F., et al. Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs. Nature 368 (1994) 643-648
17. Lyman S.D., James L., Johnson L., Brasel K., de Vries P., Escobar S.S., et al. Cloning of the human homologue of the murine flt3 Ligand: a growth factor for early hematopoietic progenitor cells. Blood 83 (1994) 2795-2801
18. Winslow G.M., Roberts A.D., Blackman M.A., and Woodland D.L. Persistence and turnover of antigen-specific CD4 T cells during chronic tuberculosis infection in the mouse. J Immunol 170 (2003) 2046-2052
19. Khader S.A., Bell G.K., Pearl J.E., Fountain J.J., Rangel-Moreno J., Cilley G.E., et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 8 4 (2007) 369-377
20. Anderson P. TB vaccines: progress and problems. Trends Immunol 22 3 (2001) 160-168
21. Banchereau J., Schuler-Thurner B., Palucka Ak, and Schuler G. Dendritic cells as vectors for therapy. Cell 106 3 (2001) 271-274
22. Martin E., Kamath A.T., Briscoe H., and Britton W.J. The combination of plasmid interleukin-12 with a single DNA vaccine is more effective than Mycobacterium bovis (bacille Calmette-Guerin) in protecting against systemic Mycobacterim avium infection. Immunology 109 2 (2003) 308-314
23. Akhiani A.A., Schon K., and Lycke N. Vaccine-induced immunity against Helicobacter pylori infection is impaired in IL-18-deficient mice. J Immunol 173 5 (2004) 3348-3356
24. Maraskovsky E., Brasel K., Teepe M., Roux E.R., Lyman S.D., Shortman K., et al. Dramatic increase in the numbers of functionally mature dendriti cells in Flt3 ligand-treated mice, multiple dendritic cell subpopulations identified. J Exp Med 184 5 (1996) 1953-1962
25. Banchereau J., and Steinman R.M. Dendritic cells and the control of immunity. Nature 392 6673 (1998) 245-252
26. Daro E., Pulendran B., Brasel K., Teepe M., Pettit D., Lynch D.H., et al. Polyethylene glycol-modified GM-CSF expands CD11b(high)CD11c(high) but not CD11b(low) CD11c(high) murine dendritic cells in vivo: a comparative analysis with Flt3 ligand. J Immunol 165 1 (2000) 49-58
27. Tussiwand R., Onai N., Mazzucchelli L., and Manz M.G. Inhibition of natural type I IFN-producing and dendritic cell development by a small molecule receptor tyrosine kinase inhibitor with Flt3 affinity. J Immunol 175 6 (2005) 3674-3680
28. Ramshaw I.A., and Ramsay A.J. The prime-boost strategy: exciting prospects for improved vaccination. Immunol Today 21 4 (2000) 163-165
29. Dunachie S.J., and Hill A.V. Prime-boost strategies for malaria vaccine development. J Exp Biol 206 Pt 21 (2003) 3771-3779
30. Li Z., Zhang H., Fan X., Zhang Y., Huang J., Liu Q., et al. DNA electroporation prime and protein boost strategy enhances humoral immunity of tuberculosis DNA vaccines in mice and non-human primates. Vaccine 24 21 (2006) 4565-4568
31. Fonseca D.M., Silva C.L., Paula M.O., Soares E.G., Marchal G., Horn C., et al. Increased levels of interferon-γ primed by culture filtrate proteins antigen and CpG-ODN immunization do not confer significant protection against Mycobacterium tuberculosis infection. Immunology 121 4 (2007) 508-517
32. Rook G.A., Dheda K., and Zumla A. Do successful tuberculosis vaccines need to be immunoregulatory rather than merely Th1-boosting?. Vaccine 23 (2005) 2115-2120
33. + T lymphocyte responses. J Immunol 172 6 (2004) 3725-3735